CA1229552A - Composes de cimetidine - Google Patents

Composes de cimetidine

Info

Publication number: CA1229552A
Authority: CA; Canada
Prior art keywords: cimetidine; tablet composition; composition according; mixed; disintegrant
Prior art date: 1984-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000458468A

Other languages

English (en)

Inventor

Audley A. Legore

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

HORNER (FRANK W) Inc

Original Assignee

HORNER (FRANK W) Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-07-09

Filing date

1984-07-09

Publication date

1987-11-24

1984-07-09 Application filed by HORNER (FRANK W) Inc filed Critical HORNER (FRANK W) Inc

1984-07-09 Priority to CA000458468A priority Critical patent/CA1229552A/fr

1987-11-24 Application granted granted Critical

1987-11-24 Publication of CA1229552A publication Critical patent/CA1229552A/fr

Status Expired legal-status Critical Current

Links

229960001380 cimetidine Drugs 0.000 title claims abstract description 100
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 title claims abstract 24
239000000203 mixture Substances 0.000 title description 24
239000007916 tablet composition Substances 0.000 claims abstract description 44
239000007884 disintegrant Substances 0.000 claims abstract description 29
239000011230 binding agent Substances 0.000 claims abstract description 26
239000000314 lubricant Substances 0.000 claims abstract description 23
238000004519 manufacturing process Methods 0.000 claims abstract description 7
229920002472 Starch Polymers 0.000 claims description 26
235000019698 starch Nutrition 0.000 claims description 26
239000008107 starch Substances 0.000 claims description 26
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 24
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 18
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
238000000034 method Methods 0.000 claims description 12
230000008569 process Effects 0.000 claims description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 18
235000019359 magnesium stearate Nutrition 0.000 claims 9
239000000546 pharmaceutical excipient Substances 0.000 abstract description 16
239000004480 active ingredient Substances 0.000 abstract description 5
230000009467 reduction Effects 0.000 abstract description 5
230000037406 food intake Effects 0.000 abstract 1
AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 77
239000003826 tablet Substances 0.000 description 64
239000008187 granular material Substances 0.000 description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
238000007906 compression Methods 0.000 description 22
230000006835 compression Effects 0.000 description 22
229920003072 Plasdone™ povidone Polymers 0.000 description 20
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 19
229940032147 starch Drugs 0.000 description 17
239000008213 purified water Substances 0.000 description 13
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 12
239000011777 magnesium Substances 0.000 description 12
229910052749 magnesium Inorganic materials 0.000 description 12
239000000243 solution Substances 0.000 description 12
238000004090 dissolution Methods 0.000 description 10
239000000463 material Substances 0.000 description 10
229920003023 plastic Polymers 0.000 description 8
239000004033 plastic Substances 0.000 description 8
208000000718 duodenal ulcer Diseases 0.000 description 6
150000003839 salts Chemical class 0.000 description 5
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
241000282320 Panthera leo Species 0.000 description 3
208000025865 Ulcer Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000009501 film coating Methods 0.000 description 3
239000007888 film coating Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
230000035876 healing Effects 0.000 description 3
239000004570 mortar (masonry) Substances 0.000 description 3
231100000397 ulcer Toxicity 0.000 description 3
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
102000010029 Homer Scaffolding Proteins Human genes 0.000 description 2
108010077223 Homer Scaffolding Proteins Proteins 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000003475 lamination Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000458468A 1984-07-09 1984-07-09 Composes de cimetidine Expired CA1229552A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000458468A CA1229552A (fr)	1984-07-09	1984-07-09	Composes de cimetidine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000458468A CA1229552A (fr)	1984-07-09	1984-07-09	Composes de cimetidine

Publications (1)

Publication Number	Publication Date
CA1229552A true CA1229552A (fr)	1987-11-24

Family

ID=4128265

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000458468A Expired CA1229552A (fr)	1984-07-09	1984-07-09	Composes de cimetidine

Country Status (1)

Country	Link
CA (1)	CA1229552A (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0347767A1 (fr) *	1988-06-23	1989-12-27	LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d.	Comprimés dispersables contenant de la cimétidine
EP0349103A1 (fr) *	1988-05-04	1990-01-03	Smith Kline & French Laboratories Limited	Comprimé à mâcher
US5275823A (en) *	1989-04-27	1994-01-04	Smith Kline & French Laboratories Ltd.	Pharmaceutical compositions
FR2723586A1 (fr) *	1994-08-11	1996-02-16	Seth Pawan	Nouvelles compositions contenant de la cimetidine et associations en derivant
US8173161B2 (en)	2002-12-04	2012-05-08	Mcneil-Ppc, Inc.	Method of administering a pharmaceutical active ingredient

1984
- 1984-07-09 CA CA000458468A patent/CA1229552A/fr not_active Expired

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0349103A1 (fr) *	1988-05-04	1990-01-03	Smith Kline & French Laboratories Limited	Comprimé à mâcher
EP0347767A1 (fr) *	1988-06-23	1989-12-27	LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d.	Comprimés dispersables contenant de la cimétidine
US5275823A (en) *	1989-04-27	1994-01-04	Smith Kline & French Laboratories Ltd.	Pharmaceutical compositions
FR2723586A1 (fr) *	1994-08-11	1996-02-16	Seth Pawan	Nouvelles compositions contenant de la cimetidine et associations en derivant
WO1996004892A1 (fr) *	1994-08-11	1996-02-22	Pharma Pass	Nouvelles compositions contenant de la cimetidine et associations en derivant
US8173161B2 (en)	2002-12-04	2012-05-08	Mcneil-Ppc, Inc.	Method of administering a pharmaceutical active ingredient

Legal Events

Date	Code	Title	Description
2004-11-24	MKEX	Expiry

Publication	Publication Date	Title
CA2301185C (fr)	2006-11-28	Preparation pharmaceutique comprenant du clodronate en tant que principe actif et de la cellulose microcristalline silicifiee en tant qu'excipient
US8877238B2 (en)	2014-11-04	Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
KR100202042B1 (ko)	1999-06-15	수마트립탄 함유 조성물
EP1410797B1 (fr)	2007-08-29	Formes orales solides comprenant du valsartan
FI117373B (fi)	2006-09-29	Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
FI101040B (fi)	1998-04-15	Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi
EP0605514B1 (fr)	1996-03-13	Preparations pharmaceutiques a liberation regulee
AU2009349125B2 (en)	2016-05-19	Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
IE881369L (en)	1988-11-08	Cimetidine containing composition
TW508242B (en)	2002-11-01	Pharmaceutical composition comprising paracetamol
US20070104785A1 (en)	2007-05-10	Tablets of linezolid form iii and processes for their preparation
US20110195120A2 (en)	2011-08-11	Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
FI89238C (fi)	1993-09-10	Foerfarande foer framstaellning av kompressionsbelagda tabletter
KR100846945B1 (ko)	2008-07-17	파라세타몰을 포함하는 연하 정제
NZ202140A (en)	1985-12-13	Delayed release nitrofurantoin tablets
US20230225977A1 (en)	2023-07-20	Formulation comprising daprodustat
FI96480C (fi)	1996-07-10	Menetelmä pitkävaikutteisen moniraetabletin valmistamiseksi
CA1229552A (fr)	1987-11-24	Composes de cimetidine
US5091191A (en)	1992-02-25	Pharmaceutical composition with improved dissolution property
EP1725217B1 (fr)	2008-08-06	Procedes pour la preparation de formes posologiques solides de chlorhydrate de valganciclovir amorphe
HK1031325B (en)	2004-09-03	Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
HK1010687B (en)	2003-09-11	Film coated tablet of paracetamol and domperidone
HK136097A (en)	1997-06-26	Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as active ingredient
MXPA00002290A (en)	2001-05-07	Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
SK285964B6 (sk)	2007-12-06	Liečivý prípravok obsahujúci fexofenadín hydrochlorid a spôsob jeho prípravy